These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33570012)

  • 1. Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats.
    Babic I; Sellers D; Else PL; Nealon J; Osborne AL; Pai N; Weston-Green K
    J Psychopharmacol; 2021 Mar; 35(3):284-302. PubMed ID: 33570012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats.
    Babic I; Gorak A; Engel M; Sellers D; Else P; Osborne AL; Pai N; Huang XF; Nealon J; Weston-Green K
    J Psychopharmacol; 2018 May; 32(5):578-590. PubMed ID: 29493378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
    Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Svensson CK; Koyuncu K; Schjerning O; Oturai PS; Kjaer A; Nielsen J; Holst JJ; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
    JAMA Psychiatry; 2017 Jul; 74(7):719-728. PubMed ID: 28601891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.
    Larsen JR; Vedtofte L; Holst JJ; Oturai P; Kjær A; Correll CU; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2014 Mar; 4(3):e004227. PubMed ID: 24667381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
    Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
    Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.
    Sharma AN; Ligade SS; Sharma JN; Shukla P; Elased KM; Lucot JB
    Metab Brain Dis; 2015 Apr; 30(2):519-27. PubMed ID: 25023888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
    Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
    Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia.
    Medak KD; Shamshoum H; Peppler WT; Wright DC
    Am J Physiol Endocrinol Metab; 2020 Dec; 319(6):E1101-E1111. PubMed ID: 33017220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
    Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
    Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
    BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats.
    Han M; Lian J; Su Y; Deng C
    J Psychopharmacol; 2022 Feb; 36(2):202-213. PubMed ID: 34694173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.
    Maagensen H; Larsen JR; Jørgensen NR; Fink-Jensen A; Vilsbøll T
    Psychiatry Res; 2021 Feb; 296():113670. PubMed ID: 33373806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.
    Weston-Green K; Huang XF; Deng C
    PLoS One; 2012; 7(3):e33548. PubMed ID: 22438946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
    Smith GC; Vickers MH; Cognard E; Shepherd PR
    Schizophr Res; 2009 Nov; 115(1):30-40. PubMed ID: 19679451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.
    Albaugh VL; Henry CR; Bello NT; Hajnal A; Lynch SL; Halle B; Lynch CJ
    Obesity (Silver Spring); 2006 Jan; 14(1):36-51. PubMed ID: 16493121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Synthetic Interfering Peptide Tat-3L4F Attenuates Olanzapine-Induced Weight Gain Through Disrupting Crosstalk Between Serotonin Receptor 2C and Protein Phosphatase and Tensin Homolog in Rats.
    Wang Y; Wang D; Chen Y; Fang X; Yu L; Zhang C
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):481-490. PubMed ID: 32710540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.
    Kaineder K; Birngruber T; Rauter G; Obermüller B; Eichler J; Münzker J; Al-Zoughbi W; Mautner SI; Torekov SS; Hartmann B; Kotzbeck P; Pieber TR
    Int J Obes (Lond); 2017 Aug; 41(8):1263-1270. PubMed ID: 28507313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.
    Li DJ; Yue Q; Liu L; Che KK; Liu XM; Hu CH
    Acta Pharmacol Sin; 2021 Aug; 42(8):1267-1279. PubMed ID: 33976388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats.
    Zheng J; Chen T; Zhu Y; Li HQ; Deng XL; Wang QH; Zhang JY; Chen LL
    Exp Biol Med (Maywood); 2015 Sep; 240(9):1165-76. PubMed ID: 25710926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment.
    Skrede S; Fernø J; Bjørndal B; Brede WR; Bohov P; Berge RK; Steen VM
    PLoS One; 2012; 7(11):e50853. PubMed ID: 23226405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.